NCODA shared a post on LinkedIn:
“EGFR mutations drive nearly a third of NSCLC cases, with prevalence as high as 50% in some populations.
This World Lung Cancer Day, explore how the latest evidence, including results from FLAURA2 and MARIPOSA, is guiding the use of next‑generation TKIs and combination regimens to extend progression‑free survival beyond first‑line resistance.
Read the full article.”
More posts featuring NCODA on OncoDaily.